Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EPS (Basic) (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed EPS (Basic) for 5 consecutive years, with -$1.99 as the latest value for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 28.16% year-over-year to -$1.99; the TTM value through Dec 2025 reached -$7.66, up 33.33%, while the annual FY2025 figure was -$7.66, 33.33% up from the prior year.
  • EPS (Basic) hit -$1.99 in Q4 2025 for Kezar Life Sciences, down from -$1.53 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.25 in Q1 2021 and bottomed at -$9.37 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$1.93, with a median of -$1.7 recorded in 2025.
  • Year-over-year, EPS (Basic) tumbled 3503.85% in 2022 and then skyrocketed 52.61% in 2023.
  • Kezar Life Sciences' EPS (Basic) stood at -$0.26 in 2021, then crashed by 3503.85% to -$9.37 in 2022, then surged by 52.61% to -$4.44 in 2023, then surged by 37.61% to -$2.77 in 2024, then rose by 28.16% to -$1.99 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$1.99, -$1.53, and -$1.87 for Q4 2025, Q3 2025, and Q2 2025 respectively.